[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:triple-negative-breast-cancer:erbb2-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Triple-negative breast cancer","ERBB2 Gene",3,[8,16,24],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04348747","Dendritic Cell Vaccines Against Her2\u002FHer3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer",[12],"Phase 2","RECRUITING","2026-08-26T02:15:14.574786Z","2026-07-05T05:32:16.794666Z",{"nct_id":17,"title":18,"phases":19,"status":21,"updated_at":22,"content_modified":23},"NCT07217990","Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer",[20],"Phase 1\u002FPhase 2","NOT_YET_RECRUITING","2026-08-26T02:19:24.527214Z","2026-05-05T02:43:27.065180Z",{"nct_id":25,"title":26,"phases":27,"status":21,"updated_at":28,"content_modified":29},"NCT07619534","Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases",[],"2026-08-26T02:15:10.362237Z","2026-06-04T01:30:07.905594Z"]